Dunad Makes Debut In Protein Degradation Space
Backed By Epidarex
Executive Summary
Based in Cambridge UK, Dunad believes it has developed a platform which is "tuneable and highly selective" and represents a new and differentiated targeted protein degradation approach.
You may also be interested in...
Dunad Bags Big Pharma Partner In Protein Degradation Deal With Novartis
Dunad is out-licensing its targeted protein degradation and covalent drug platform to Novartis in a deal that could be worth up to $1.3bn.
Monte Rosa Hits The Heights With $96m Cash Hike
The Boston-based biotech has secured a substantial new investment for its protein degradation platform which has the potential to treat currently undruggable cancers in a new way.
Protein Degradation Leader Nurix Prepares First Clinical Trial
After raising nearly $330m this year, via a financing and IPO, the company is gearing up for a first-in-human trial using its platform technology.